Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules – A randomized controlled trialArchived

ECDC comment

​4CMenB has the potential to reduce serogroup B meningococcal disease substantially. Despite its potential, the vaccine may have some limitations, and it remains to be seen if booster doses will be required to sustain protection. However, for the first time, vaccines to prevent all five of the serogroups that cause most meningococcal disease worldwide might become available.